1. CRISPR Therapeutics reported reduced expenses and a slow launch of Casgevy, leading to a revenue miss but a narrowed net loss. 2. The company's financial health remains strong with a cash runway of approximately 5 years. 3. CRISPR's CAR-T therapies show promise but lack an innovative edge; ambitious projects in diabetes and cardiovascular disease are high-risk moonshots. 4. CRSP stock is a cautious 'hold' due to its high-risk/high-reward profile.